Axial Spondyloarthritis – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Axial Spondyloarthritis – Pipeline Review, H2 2016’, provides an overview of the Axial Spondyloarthritis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Axial Spondyloarthritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Axial Spondyloarthritis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Axial Spondyloarthritis

The report reviews pipeline therapeutics for Axial Spondyloarthritis by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Axial Spondyloarthritis therapeutics and enlists all their major and minor projects

The report assesses Axial Spondyloarthritis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Axial Spondyloarthritis

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Axial Spondyloarthritis

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Axial Spondyloarthritis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Eli Lilly and Company

Johnson & Johnson

Novartis AG

Panacea Biotec Ltd

Sandoz International GmbH

UCB SA

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Axial Spondyloarthritis Overview 7

Therapeutics Development 8

Pipeline Products for Axial Spondyloarthritis - Overview 8

Axial Spondyloarthritis - Therapeutics under Development by Companies 9

Axial Spondyloarthritis - Pipeline Products Glance 10

Late Stage Products 10

Early Stage Products 11

Unknown Stage Products 12

Axial Spondyloarthritis - Products under Development by Companies 13

Axial Spondyloarthritis - Companies Involved in Therapeutics Development 14

Eli Lilly and Company 14

Johnson & Johnson 15

Novartis AG 16

Panacea Biotec Ltd 17

Sandoz International GmbH 18

UCB SA 19

Axial Spondyloarthritis - Therapeutics Assessment 20

Assessment by Monotherapy Products 20

Assessment by Target 21

Assessment by Mechanism of Action 23

Assessment by Route of Administration 25

Assessment by Molecule Type 27

Drug Profiles 29

adalimumab biosimilar - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

adalimumab biosimilar - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

adalimumab biosimilar - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

adalimumab biosimilar - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

certolizumab pegol - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

Drug to Antagonize ROR-Gamma for Psoriasis, Psoriatic Arthritis and Axial Spondyloarthritis - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

etanercept biosimilar - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

ixekizumab - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

secukinumab - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

ustekinumab - Drug Profile 68

Product Description 68

Mechanism Of Action 68

R&D Progress 68

Axial Spondyloarthritis - Dormant Projects 75

Axial Spondyloarthritis - Product Development Milestones 76

Featured News & Press Releases 76

Nov 11, 2016: UCB Presents Data on Cimzia (certolizumab pegol) at 2016 ACR/ARHP Annual Meeting 76

Oct 25, 2016: Certolizumab pegol (Cimzia) AutoClicks Prefilled Pen - a New Self-injection Device Designed in Collaboration With Patients and Good Grips - is Now Available in the UK on the NHS 79

Jun 08, 2016: UCB commitment to addressing real world patient needs on display at the Annual European Congress of Rheumatology (EULAR 2016) 80

Nov 06, 2015: UCB Presents Latest Research from Immunology Portfolio at American College of Rheumatology Annual Meeting 83

Nov 14, 2014: UCB Shows Strong Scientific Presence On Certolizumab pegol (CIMZIA) At Leading Rheumatology Meeting 88

Sep 20, 2013: UCB receives CHMP positive opinion for Cimzia in severe active axial spondyloarthritis 91

Jul 24, 2013: U.S. FDA Arthritis Advisory Committee Votes On Cimzia For Treatment of Adults with Active Axial Spondyloarthritis, Including Patients with Ankylosing Spondylitis 92

Jun 14, 2013: UCB's Certolizumab Pegol Rapidly Improves Pain, Fatigue And Physical Function In axSpA Patients In Phase III Study 93

Feb 20, 2013: UCB Announces Regulatory Filings For Cimzia To Treat Psoriatic Arthritis And Axial Spondyloarthritis 95

Nov 13, 2012: UCB Announces Presentation Of Phase III Trial Results Of Certolizumab Pegol In Axial Spondyloarthritis At ACR 2012 Annual Meeting 96

Nov 09, 2012: UCB To Present New Data On Certolizumab Pegol At ACR's 2012 Annual Scientific Meeting 98

Apr 16, 2012: UCB Announces Positive Top-Line Phase III Results Of Cimzia In Axial Spondyloarthritis And Ankylosing Spondylitis 100

Appendix 102

Methodology 102

Coverage 102

Secondary Research 102

Primary Research 102

Expert Panel Validation 102

Contact Us 102

Disclaimer 103

List of Tables

List of Tables

Number of Products under Development for Axial Spondyloarthritis, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Comparative Analysis by Late Stage Development, H2 2016 10

Comparative Analysis by Early Stage Development, H2 2016 11

Comparative Analysis by Unknown Stage Development, H2 2016 12

Products under Development by Companies, H2 2016 13

Axial Spondyloarthritis – Pipeline by Eli Lilly and Company, H2 2016 14

Axial Spondyloarthritis – Pipeline by Johnson & Johnson, H2 2016 15

Axial Spondyloarthritis – Pipeline by Novartis AG, H2 2016 16

Axial Spondyloarthritis – Pipeline by Panacea Biotec Ltd, H2 2016 17

Axial Spondyloarthritis – Pipeline by Sandoz International GmbH, H2 2016 18

Axial Spondyloarthritis – Pipeline by UCB SA, H2 2016 19

Assessment by Monotherapy Products, H2 2016 20

Number of Products by Stage and Target, H2 2016 22

Number of Products by Stage and Mechanism of Action, H2 2016 24

Number of Products by Stage and Route of Administration, H2 2016 26

Number of Products by Stage and Molecule Type, H2 2016 28

Axial Spondyloarthritis – Dormant Projects, H2 2016 75

List of Figures

List of Figures

Number of Products under Development for Axial Spondyloarthritis, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Comparative Analysis by Late Stage Development, H2 2016 10

Assessment by Monotherapy Products, H2 2016 20

Number of Products by Targets, H2 2016 21

Number of Products by Stage and Targets, H2 2016 21

Number of Products by Mechanism of Actions, H2 2016 23

Number of Products by Stage and Mechanism of Actions, H2 2016 23

Number of Products by Routes of Administration, H2 2016 25

Number of Products by Stage and Routes of Administration, H2 2016 25

Number of Products by Molecule Types, H2 2016 27

Number of Products by Stage and Molecule Types, H2 2016 27

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports